- Baseimmune facilitates growth with move to the Apex Building, part of the Tribeca development - London’s latest grow-on lab space
- Latest sign-up increases LBIC’s pre-let occupancy at Apex to 35%
LONDON, UK 19th August 2024: London BioScience Innovation Centre (LBIC) is delighted to announce that it has entered into an Agreement for Lease with Baseimmune Ltd. The novel vaccine developer will occupy 3,350 sq ft of lab and office space in LBIC’s new, fully fitted, grow-on space within the Apex building, located in the heart of the King’s Cross Knowledge Quarter. This increases pre-let occupancy levels to 35% of LBIC’s total lettable space in this premium new facility.
Building on its existing provision just a few minutes’ walk from King’s Cross St Pancras, LBIC’s Apex facility provides additional scale-up, high-spec lab and write up space to facilitate growth across its expanding customer base; broadening its value proposition and cementing its attractiveness as a world-leading destination for bioscience R&D in London.
Baseimmune, a biotech company that uses proprietary deep learning AI to predict future pathogen mutations to generate novel vaccines, first established its startup activities with LBIC in 2022. This move provides the grow-on space it requires whilst continuing to provide the team with specialist lab support and hands on scientific services delivered by the expert operations and facilities team at LBIC.
The Apex is the first of four buildings to be delivered by the Reef Group as part of the wider Tribeca development, London’s largest purpose-built life sciences development bridging the gap between life and science. Once complete the development will offer 600,000 sq ft of lab space at the centre of London’s biotech cluster, whilst providing clients with access to a vibrant and diverse mix of culture, shopping and eateries alongside significant public realm.
Dr Rich Ferrie, CEO, LBIC commented: “We place a high value on our existing relationship with the founding team at Baseimmune and I am delighted that they have chosen to drive the next phase of their growth at our fantastic new Apex facility. We are thrilled at how the market is responding to our new space and pre-letting activity is ahead of schedule. We will be making further announcements on progress in the lead up to launch later this year.”
Joshua Blight, CEO and Co-Founder, Baseimmune, said: “We couldn’t be more excited about our expansion to the Apex. In a market where the availability of lab estate is growing, it is the team behind the space which enables a rapidly growing startup to succeed and in lab-enabled space this is truer than ever and underpins so many of your milestones and inflection points. Aligning with the best team is one of the keys to success and for us that’s the experienced team at LBIC.”
Alisje Churchyard, Head of R&D Operations, Baseimmune, added: “We are delighted to be part of the vibrant scientific community at LBIC, and this expansion to the Apex allows us to grow our team and still benefit from the support and services on offer. With comprehensive services like waste management, sterilisation, and supply of ice and gas handled by the LBIC Facilities team, we can dedicate our efforts to advancing our innovative research.”
For more information on all LBIC facilities please contact Director of Business Development and Marketing, Amanda Keightley-Pugh, via: lbicenquries@rvc.ac.uk, or visit: lbic.com.
